2023-03-23 11:27:27 ET
- Bayer ( OTCPK:BAYZF ) and Orion Corp. ( OTCPK:ORINY ) have started a late-stage trial examining Nubeqa (darolutmaide) in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence.
- The indication would be for patients who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline.
- The trial will examine Nubeqa plus androgen deprivation therapy ("ADT") versus ADT alone.
- Nubeqa is already approved for those with non-metastatic castration-resistant prostate cancer, who are at high risk of developing metastatic disease, and metastatic hormone-sensitive prostate cancer.
- Read why Seeking Alpha contributor Daniel Schonberger argues that Bayer ( OTCPK:BAYRY ) is unvervalued and a buy.
For further details see:
Bayer, Orion begin phase 3 trial of Nubeqa to expand prostate cancer indication